Why do some COVID-19 patients have a severe disease progression while other barely show any symptoms?
In the project EPI-Dx – Epidemiological investigation on peptide signatures, immunity, genetic predisposition as well as changes in SARS-CoV-2 – researchers from ATLAS Biolabs GmbH, invent Diagnostica GmbH and Microdiscovery GmbH try to answer this and similar questions, by investigating if genetic variants play a role in the disease progression. For this serological, genetic and PCR-Tests are going to look at the variations in the genomes of both the host and the pathogen.
Learn more about the EPI-Dx project on the Project-Website – there you can also access the research tool designed by the project coordinator Dr. Karsten Heidtke that allows a targeted search of relevant SARS-CoV SNPs.
This project is funded by the Federal Ministry of Education and Research (grant number 03COV21).



